Primary tumor location is an important predictive factor for wild‐type KRAS metastatic colon cancer treated with cetuximab as front‐line bio‐therapy. Issue 3 (3rd March 2016)

• Record Type: Journal Article
• Authors: Lu, Hsueh‐Ju; Lin, Jen‐Kou; Chen, Wei‐Shone; Jiang, Jeng‐Kai; Yang, Shung‐Haur; Lan, Yuan‐Tzu; Lin, Chun‐Chi; Chang, Shih‐Ching; Teng, Hao‐Wei
• Is Part Of: Asia-Pacific journal of clinical oncology. Volume 12:Issue 3(2016)
• Page Start: 207
• Page End: 215
• Publication Date: 2016-03-03
• Subjects: cetuximab -- KRAS wild‐type -- metastatic colon cancer -- primary tumor location; Oncology -- Pacific Area -- Periodicals; Cancer -- Treatment -- Pacific Area -- Periodicals; Cancer -- Pacific Area -- Periodicals; Cancer -- Treatment -- Periodicals; 616.9940095
• DOI: 10.1111/ajco.12469
• Languages: English
• ISSNs: 1743-7555

Abstract

Abstract: Introduction: Left‐ and right‐sided colon cancers were significantly different in epidemiologic, clinical and histological parameters. However, the impact of primary tumor location in metastatic colon cancer treated with front‐line targeted triplet regimens is unclear, particularly in Asian populations. Methods: A total of 121 patients with KRAS exon 2 codon 12/13 wild‐type metastatic colon cancer were enrolled between January 2007 and December 2013. All patients received one target agent, such as cetuximab or bevacizumab, as a front‐line targeted triplet regimen. The impact of primary tumor location for cetuximab and bevacizumab groups was analyzed, respectively. Results: In cetuximab group, left‐sided metastatic colon cancer was superior to right‐sided metastatic colon cancer in objective response rate (70.1% vs 33.3%, P = 0.024), progression‐free survival (15.0 vs 5.3 months, P < 0.001) and overall survival (35.8 vs 14.4 months, P = 0.031 ) . Primary tumor location was an independent prognostic factor for progression‐free survival (hazard ratio 0.240, 95% confidence interval 0.114–0.508, P < 0.001). However, in the bevacizumab group, there were no differences in outcomes for either side. Primary tumor location was insignificant for progression‐free survival and overall survival in univariate analysis. Conclusion: Left‐sided primary tumors were favored in cetuximab‐based front‐line targeted triplet regimen for metastatic colon cancer.